Udenafil is a long-lasting PDE-5 inhibitor, and so it works in the same mechanism as Viagra, i.e. it relaxes blood vessels and allows more blood to flow to the genitals, which improves the man’s ability to achieve and maintain a firm erection during sexual arousal.

This drug is already approved and marketed under the brand name Zydena in some countries, including Korea and Russia. Dong-A is crossing fingers that in a couple of years they will be granted marketing authorization for Udenafil in the US and EU.

If it gets approved by the FDA, Zydena (Udenafil) will become the fourth prescription treatment option for ED patients that will compete with Viagra (sildenafil citrate), Cialis (tadalafil), and Levitra (vardenafil). More competition is always in favor of consumers who get more options, from which they can choose what is best for them in terms of results, safety, and price (after consulting a doctor, of course).